

Open Peer Review on Qeios

Certolizumab Pegol

National Cancer Institute

Source

National Cancer Institute. <u>Certolizumab Pegol</u>. NCI Thesaurus. Code C80972.

A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile.

Qeios ID: OGTPYR · https://doi.org/10.32388/OGTPYR